| Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights |
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society of Gene and Cell Therapy (ASGCT) 28 th Annual Meeting Cash runway into 1Q 2027 PHILADELPHIA, May 13, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights. “We made steady progress in executing against our core operational objectives this quarter as we focus on the enrollment of FTD-GRN and FTD-C9orf72 patients in our ongoing global Phase 1/2 upliFT-D trial of PBFT02,” said Will Chou, M.D. |
globenewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know |
Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-07 15:06:18 |
Czytaj oryginał (ang.) |
| Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights |
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights. “We are pleased to report strong performance in 2024 as we meaningfully advanced our PBFT02 program, delivering promising data in FTD-GRN patients showing robust, durable progranulin expression and early evidence of improvement in a disease progression biomarker. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio to Participate in Upcoming Investor Conferences |
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates |
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data |
globenewswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio assumed with an Outperform at Wedbush |
Wedbush assumed coverage of Passage Bio with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage's upsized IPO, but the current valuation looks to be a "deep discount" compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors. |
https://thefly.com |
2024-11-29 08:52:18 |
Czytaj oryginał (ang.) |
| Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference |
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET. |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference |
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) |
globenewswire.com |
2024-10-24 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference |
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. |
globenewswire.com |
2024-09-23 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio Welcomes Tom Kassberg to Board of Directors |
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. |
globenewswire.com |
2024-09-10 11:52:00 |
Czytaj oryginał (ang.) |
| Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference |
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET. |
globenewswire.com |
2024-08-30 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights |
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights. “This has been a pivotal quarter for our company, marked by significant momentum in our upliFT-D trial, increased clarity around our strategy to expand PBFT02 into additional adult neurodegenerative indications, and out-licensing of our pediatric lysosomal storage disorder programs,” said Will Chou, M.D. |
globenewswire.com |
2024-08-08 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration |
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson |
globenewswire.com |
2024-08-01 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients |
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations |
globenewswire.com |
2024-07-16 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-06-18 14:35:19 |
Czytaj oryginał (ang.) |
| Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference |
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 4:00 p.m. ET. |
globenewswire.com |
2024-06-05 11:30:00 |
Czytaj oryginał (ang.) |
| Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award |
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award. |
globenewswire.com |
2024-05-21 12:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy |
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-05-16 17:01:25 |
Czytaj oryginał (ang.) |
| Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights |
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024 and provided recent business highlights. |
globenewswire.com |
2024-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit |
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024 at 9:00 a.m. ET. |
globenewswire.com |
2024-04-22 11:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know |
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-03-07 15:01:14 |
Czytaj oryginał (ang.) |
| Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights |
PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided recent business highlights. |
globenewswire.com |
2024-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| Passage Bio to Participate in Upcoming Investor Conferences |
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| 7 Analyst-Backed Stocks With Promising 10-Bagger Potential |
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don't always get the love from retail investors. |
investorplace.com |
2024-02-01 21:09:57 |
Czytaj oryginał (ang.) |
| Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference |
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m. ET. |
globenewswire.com |
2024-01-31 09:30:00 |
Czytaj oryginał (ang.) |